MII IG Kerndatensatz-Modul Molekulargenetischer Befundbericht - Downloaded Version 2027.0.0-ballot.1 See the Directory of published versions

• Narrativer Inhalt
• XML
• JSON

: mii-exa-molgen-therapeutische-implikation-fgfr2-fusion

Raw xml | Download

<Observation xmlns="http://hl7.org/fhir">
  <id value="mii-exa-molgen-therapeutische-implikation-fgfr2-fusion"/>
  <meta>
    <profile
             value="https://www.medizininformatik-initiative.de/fhir/ext/modul-molgen/StructureDefinition/therapeutische-implikation|2027.0.0-ballot.1"/>
    <profile
             value="http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication|3.0.0"/>
  </meta>
  <language value="de"/>
  <text>
    <status value="generated"/>
    <div xml:lang="de" lang="de"><hr/><p><b>German</b></p><hr/><p class="res-header-id"><b>Generated Narrative: Observation mii-exa-molgen-therapeutische-implikation-fgfr2-fusion</b></p><a name="de-mii-exa-molgen-therapeutische-implikation-fgfr2-fusion"> </a><a name="de-hcmii-exa-molgen-therapeutische-implikation-fgfr2-fusion"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profiles: <a href="StructureDefinition-mii-pr-molgen-therapeutische-implikation.html">MII PR MolGen Therapeutische Implikation</a> version: 2027.0.0-ballot.1, <a href="http://hl7.org/fhir/uv/genomics-reporting/STU3/StructureDefinition-therapeutic-implication.html">Therapeutic Implication</a> version: 3.0.0</p></div><p><b>status</b>: Final</p><p><b>category</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/observation-category laboratory}">Laboratory</span>, <span title="Codes:{http://terminology.hl7.org/CodeSystem/v2-0074 GE}">Genetik</span></p><p><b>code</b>: <span title="Codes:{http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs therapeutic-implication}">Therapeutic Implication</span></p><p><b>subject</b>: <a href="Patient-mii-exa-molgen-patient-fgfr2-fusion.html">Anonymous Patient Female, DoB: 1964-05 ( pseudonymized (use: usual, ))</a></p><p><b>effective</b>: 2022-11-30</p><p><b>performer</b>: <a href="Practitioner-mii-exa-molgen-practitioner-lab.html">Practitioner Dr. Daniel Schmidt(official)</a></p><p><b>derivedFrom</b>: <a href="Observation-mii-exa-molgen-variante-fgfr2-fusion.html">Observation Genetic variant assessment</a></p><blockquote><p><b>component</b></p><p><b>code</b>: <span title="Codes:{http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs conclusion-string}">Conclusion Text</span></p><p><b>value</b>: Hochselektiver FGFR2-Inhibitor RLY-4008 bei Patienten mit Cholangiokarzinomen und anderen soliden Tumoren, mit oder ohne FGFR- gerichtete Vortherapie.</p></blockquote><blockquote><p><b>component</b></p><p><b>code</b>: <span title="Codes:{http://loinc.org 51963-7}">Medication assessed [ID]</span></p><p><b>value</b>: <span title="Codes:{http://www.whocc.no/atc L01EN}, {http://snomed.info/sct 1162485005}">Fibroblasten-Wachstumsfaktor-Rezeptor (FGFR)-Tyrosinkinase-Inhibitoren</span></p></blockquote><blockquote><p><b>component</b></p><p><b>code</b>: <span title="Codes:{http://loinc.org 93044-6}">Level of evidence</span></p><p><b>value</b>: <span title="Codes:">m1c</span></p></blockquote><blockquote><p><b>component</b></p><p><b>code</b>: <span title="Codes:{http://loinc.org 81259-4}">Associated phenotype</span></p><p><b>value</b>: <span title="Codes:{http://snomed.info/sct 109842005}, {http://fhir.de/CodeSystem/bfarm/icd-10-gm C22.1}">Intrahepatic bile duct carcinoma (disorder)</span></p></blockquote></div>
  </text>
  <status value="final"/>
  <category>
    <coding>
      <system
              value="http://terminology.hl7.org/CodeSystem/observation-category"/>
      <code value="laboratory"/>
      <display value="Laboratory"/>
    </coding>
  </category>
  <category>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/v2-0074"/>
      <code value="GE"/>
    </coding>
  </category>
  <code>
    <coding>
      <system
              value="http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs"/>
      <code value="therapeutic-implication"/>
      <display value="Therapeutic Implication"/>
    </coding>
  </code>
  <subject>🔗 
    <reference value="Patient/mii-exa-molgen-patient-fgfr2-fusion"/>
  </subject>
  <effectiveDateTime value="2022-11-30"/>
  <performer>🔗 
    <reference value="Practitioner/mii-exa-molgen-practitioner-lab"/>
  </performer>
  <derivedFrom>🔗 
    <reference value="Observation/mii-exa-molgen-variante-fgfr2-fusion"/>
  </derivedFrom>
  <component>
    <code>
      <coding>
        <system
                value="http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs"/>
        <code value="conclusion-string"/>
      </coding>
    </code>
    <valueString
                 value="Hochselektiver FGFR2-Inhibitor RLY-4008 bei Patienten mit Cholangiokarzinomen und anderen soliden Tumoren, mit oder ohne FGFR- gerichtete Vortherapie."/>
  </component>
  <component>
    <code>
      <coding>
        <system value="http://loinc.org"/>
        <code value="51963-7"/>
        <display value="Medication assessed [ID]"/>
      </coding>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://www.whocc.no/atc"/>
        <code value="L01EN"/>
        <display
                 value="Fibroblasten-Wachstumsfaktor-Rezeptor (FGFR)-Tyrosinkinase-Inhibitoren"/>
      </coding>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="1162485005"/>
        <display
                 value="Substance with fibroblast growth factor receptor inhibitor mechanism of action (substance)"/>
      </coding>
    </valueCodeableConcept>
  </component>
  <component>
    <code>
      <coding>
        <system value="http://loinc.org"/>
        <code value="93044-6"/>
      </coding>
    </code>
    <valueCodeableConcept>
      <text value="m1c"/>
    </valueCodeableConcept>
  </component>
  <component>
    <code>
      <coding>
        <system value="http://loinc.org"/>
        <code value="81259-4"/>
      </coding>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="109842005"/>
        <display value="Intrahepatic bile duct carcinoma (disorder)"/>
      </coding>
      <coding>
        <system value="http://fhir.de/CodeSystem/bfarm/icd-10-gm"/>
        <version value="2024"/>
        <code value="C22.1"/>
        <display value="Intrahepatisches Gallengangskarzinom"/>
      </coding>
    </valueCodeableConcept>
  </component>
</Observation>